NeurologyLive® Friday 5 — August 9, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: FDA Action Update, July 2024: Approvals, Designations, and Clearances

Catch up on any of the neurology news headlines you may have missed over the course of July 2024, compiled all into one place by the NeurologyLive^® team.

2: Exploring AI-Powered Music Therapy as a Solution to Chronic Pain Management and the Opioid Crisis

Neal K. Shah, CEO of CareYaya Health Technologies, explores the potential of AI-enhanced, neurotech-powered music therapy as a revolutionary solution to chronic pain management and the opioid crisis.

3: The Need for Flexibility and Patient-Centered Approaches in Clinical Trials for Cervical Dystonia: Anna Castagna, MD

The consultant neurologist at Fondazione Don Carlo Gnocchi ONLUS stressed how new clinical trial designs for cervical dystonia should incorporate more flexible and patient-centered approaches, including new measurement scales and the use of technology. [WATCH TIME: 5 minutes]

4: NeuroVoices: Stina Saunders, PhD, on the Utility of the Electronic Person-Specific Outcome Measure on Brain Health

The personalized medicine lead at Linus Health provided clarity on a new outcome measure that captures various perspectives about what matters to individuals and their brain health.

5: Current and Emerging Treatment Options for Neurofibromatosis Type 1 Related Plexiform Neurofibroma

A healthcare expert examines Mirdametinib as an investigational treatment for NF1-PN, focusing on its potential role in managing the condition in adolescents and adults who have moved beyond pediatric care.